Detecting androgen receptor (AR), AR variant 7 (AR-V7), prostate-specific membrane antigen (PSMA), and prostate-specific antigen (PSA) gene expression in CTCs and plasma exosome-derived cfRNA in patients with metastatic castration-resistant prostate cancer (mCRPC) by integrating the VTX-1 CTC isolation system with the QIAGEN AdnaTest

Detecting androgen receptor (AR), AR variant 7 (AR-V7), prostate-specific membrane antigen (PSMA), and prostate-specific antigen (PSA) gene expression in CTCs and plasma exosome-derived cfRNA in patients with metastatic castration-resistant prostate cancer (mCRPC) by integrating the VTX-1 CTC isolation system with the QIAGEN AdnaTest

Abstract Background Therapies for metastatic castration-resistant prostate cancer (mCRPC) include targeting the androgen receptor (AR) with androgen receptor inhibitors (ARIs) and prostate-specific membrane antigen (PSMA). Having the ability to detect AR, AR splice variant 7 (AR-V7), or PSMA in circ...

Full description

Bibliographic Details
Main Authors: Haiyan E. Liu, Meghah Vuppalapaty, Christian R. Hoerner, Colin P. Bergstrom, Michael Chiu, Clementine Lemaire, James Che, Amanpreet Kaur, Adam Dimmick, Sean Liu, Thomas J. Metzner, Menna Araya, Steve Crouse, Markus Sprenger-Haussels, Martin Schlumpberger, John T. Leppert, Siegfried Hauch, Elodie Sollier, Alice C. Fan
Format: Article
Language:English
Published: BMC 2024-04-01
Series:BMC Cancer
Subjects:
Prostate cancer
Castration resistance
Androgen receptor inhibitors
Therapeutic resistance
AR-V7
PSMA
Online Access:https://doi.org/10.1186/s12885-024-12139-3

Internet

https://doi.org/10.1186/s12885-024-12139-3

Similar Items